EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?

Alexander Weissensee, Alan Daniel Sidandy, Clemens Mingels, Nasir Gözlügöl, Radi Saiyed Alsheikh, Mohamed Shelan, Federico Caobelli, Robert Seifert, Axel Rominger, Ali Afshar-Oromieh

Nuklearmedizin - NuclearMedicine · 2026-11-12

DOI: 10.1055/a-2981-3134 ↗
AbstractBibliografische Angaben

Abstract

Abstract Prostate cancer (PC) lesions usually show increasing uptake of prostate-specific membrane antigen (PSMA) ligands over time. We investigated whether the intensity changes of PSMA-ligand uptake on dual-time-point positron emission tomography/computed tomography (PET/CT) can predict the response to [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT). Nineteen patients who underwent dual-time-point [18F]PSMA-1007 PET/CT before PSMA-RLT were retrospectively analysed. Standardised uptake values were measured for local prostate cancer lesions and lymph node, bone, and organ metastases. These groups were compared for maximum standardised uptake value (SUVmax) differences between standard and late scans. Using Firth’s bias-reduced logistic regression, we assessed whether change in SUVmax between standard and late scans (ΔSUVmax) correlates with long-term biochemical response to PSMA-RLT. We analysed 355 PC lesions (14 local tumours, 171 bone, 132 lymph node, and 38 organ metastases). Across all lesions, the median SUVmax in late scans was 15.2% higher than that in standard scans (p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →